Drugs / Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)
Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06131554 | Mar → Jul 2024 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07374510 Comparator | Jan → Sep 2026 overdue | meningococcal meningitis | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07505823 Comparator | Mar 2026 → Apr 2027 expected | meningitis, meningococcal infection | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-07-19 | CanSino Biologics Inc. | Regulatory CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years cansinotech.com ↗
July 19, 2026 – CanSino Biologics Inc. ("CanSinoBIO" or the "Company", HKEX: 06185, SSE: 688185) today announced that the National Medical Products Administration of China ("NMPA") has accepted the supplemental application for Menhycia® (Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, CRM197 Carrier, "MCV4") to expand its approved indication to the population aged 3 months to 17 years. |
| 2026-06-25 | CanSino Biologics Inc. | Regulatory CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach cansinotech.com ↗ |
| 2026-02-24 | CanSino Biologics Inc. | Regulatory Breaking News | CanSino Biologics' Menhycia® (MCV4) Expands Age Indication to Include individuals up to age 6, Enhancing Meningococcal Prevention for School-aged children cansinotech.com ↗ |
| 2025-02-06 | CanSino Biologics Inc. | Regulatory CanSinoBIO Obtained Halal Decree of Menhycia® in Indonesia cansinotech.com ↗
Menhycia®[Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), MCV4] has been granted Halal Decree by the Assessment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia (LPPOM MUI), further reinforcing our commitment to providing innovative, high-quality, affordable and culturally respectful solutions. |
| 2021-12-29 | CanSino Biologics Inc. | Regulatory CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China cansinotech.com ↗
CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China (“NMPA”) granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (“MCV4”, trade name: Menhycia™), making it the first of its kind to be authorized in China. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-19 | CanSino Biologics Inc. | CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years cansinotech.com ↗ |
| 2026-06-25 | CanSino Biologics Inc. | CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach cansinotech.com ↗ |
| 2026-02-24 | CanSino Biologics Inc. | Breaking News | CanSino Biologics' Menhycia® (MCV4) Expands Age Indication to Include individuals up to age 6, Enhancing Meningococcal Prevention for School-aged children cansinotech.com ↗ |
| 2025-02-06 | CanSino Biologics Inc. | CanSinoBIO Obtained Halal Decree of Menhycia® in Indonesia cansinotech.com ↗ |
| 2021-12-29 | CanSino Biologics Inc. | CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China cansinotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) | “Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)” NCT07505823 ↗ |
| Modality | Vaccine | “Meningococcal Conjugate Vaccine” NCT06131554 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06131554 ↗ |